Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  De Vera, Mary A ^a   Sadatsafavi, Mohsen ^a,b   Tsao, Nicole W ^a   Lynd, Larry D ^a   Lester, Richard ^a   Gastonguay, Louise ^a   Galo, Jessica ^a   FitzGerald, J Mark ^a   Brasher, Penelope ^b   Marra, Carlo A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Research Pavilion   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Asthma; Cluster randomized controlled trial; Community pharmacy; Inhaled corticosteroids; Medication adherence; Pharmacy practice research

Indexed keywords

CORTICOSTEROID; ANTIASTHMATIC AGENT;

ADOLESCENT; ARTICLE; ASTHMA; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EMPOWERMENT; FOLLOW UP; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; HUMAN; INTERACTIVE SHORT MESSAGE SERVICE; INTERVENTION STUDY; MEDICATION COMPLIANCE; MOBILE PHONE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TEXT MESSAGING; ADULT; ATTITUDE TO HEALTH; BEHAVIOR; BRITISH COLUMBIA; CLINICAL COMPETENCE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; ECONOMICS; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; PHARMACY; PROFESSIONAL STANDARD; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; ATTITUDE OF HEALTH PERSONNEL; BRITISH COLUMBIA; CELL PHONES; CLINICAL COMPETENCE; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HEALTH CARE COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PHARMACISTS; POWER (PSYCHOLOGY); PROFESSIONAL ROLE; TEXT MESSAGING; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924708675     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-488     Document Type: Article

References (64)

1. Kim H, Mazza J: Asthma. Allergy Asthma Clin Immun 2011, 10:S2.
2. Braman SS: The global burden of asthma. Chest 2006,130(Suppl 1):4S-12S.
3. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478. 10.1111/j.1398-9995.2004.00526.x
4. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM: Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24. 10.1186/1471-2466-9-24
5. Statistics Canada: Asthma, by Sex, Provinces and Territories. Available from: http://www.statcan.gc.ca/pub/82-625-x/2011001/article/11458-eng.htm.
6. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178. 10.1183/09031936.00138707
7. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, Pirina P, Carrozzi L, Dallari R, De Togni A, de Marco R: Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006, 141:189-198. 10.1159/000094898
8. The National Asthma Education Prevention Program (NAEPP II): Guidelines for the Treatment of Asthma: Implications for the Pharmacist. St. Louis, Missouri: St. Louis College of Pharmacy; 2000.
9. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP: Adherence to asthma controller medication regimens. Respir Med 2005, 99:1263-1267. 10.1016/j.rmed.2005.03.002
10. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL: Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med 1998, 157:1810-1817. 10.1164/ajrccm.157.6.9712007
11. Bender BG, Pedan A, Varasteh LT: Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol 2006, 118:899-904. 10.1016/j.jaci.2006.07.002
12. Gamble J, Stevenson M, McClean E, Heaney LG: The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009, 180:817-822. 10.1164/rccm.200902-0166OC
13. Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, Green RH: The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012, 67:751-753. 10.1136/thoraxjnl-2011-201096
14. Williams LK, Joseph CL, Peterson EL, Wells K, Wang M, Chowdhry VK, Walsh M, Campbell J, Rand CS, Apter AJ, Lanfear DE, Tunceli K, Pladevall M: Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007, 120:1153-1159. 10.1016/j.jaci.2007.08.020
15. Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, Chowdhry VK, Favro D, Lanfear DE, Pladevall M: Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011, 128:1185-1191. 10.1016/j.jaci.2011.09.011
16. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, Ownby DR, Johnson CC: Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004, 114:1288-1293. 10.1016/j.jaci.2004.09.028
17. Rand CS, Wise RA: Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994, 149:S69-S76. discussion S7-8 10.1164/ajrccm/149.2_Pt_2.S69
18. Bender BG, Rand C: Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004, 4:191-195. 10.1097/00130832-200406000-00009
19. Boulet LP, Vervloet D, Magar Y, Foster JM: Adherence: the goal to control asthma. Clin Chest Med 2012, 33:405-417. 10.1016/j.ccm.2012.06.002
20. Blais L, Suissa S, Boivin JF, Ernst P: First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998, 53:1025-1029. 10.1136/thx.53.12.1025
21. Ernst P, Spitzer WO, Suissa S, Cockcroft D, Habbick B, Horwitz RI, Boivin JF, Mcnutt M, Buist AS: Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. Jama-J Am Med Assoc 1992, 268:3462-3464. 10.1001/jama.1992.03490240070039
22. Suissa S, Ernst P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937-944. 10.1067/mai.2001.115653
23. Suissa S, Ernst P, Kezouh A: Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002, 57:880-884. 10.1136/thorax.57.10.880
24. Knapp KK, Paavola FG, Maine LL, Sorofman B, Politzer RM: Availability of primary care providers and pharmacists in the United States. J Am Pharm Assoc 1999, 39:127-135.
25. Garcia-Cardenas V, Sabater-Hernandez D, Kenny P, Martinez-Martinez F, Faus MJ, Benrimoj SI: Effect of a pharmacist intervention on asthma control. A cluster randomised trial. Respir Med 2013, 107:1346-1355. 10.1016/j.rmed.2013.05.014
26. Armour C, Bosnic-Anticevich S, Brillant M, Burton D, Emmerton L, Krass I, Saini B, Smith L, Stewart K: Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax 2007, 62:496-502. 10.1136/thx.2006.064709
27. McLean W, Gillis J, Waller R: The BC community pharmacy asthma study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J 2003, 10:195-202.
28. International Telecommunication Union: Key Global Telecom Indicators for the World Telecommunication Service Sector. 2010. Available from: https://www.census.gov/compendia/statab/2012/tables/12s1391.pdf
29. Kay M: mHealth: New Horizons for Health Through Mobile Technologies. Geneva, Switzerland: World Health Organization; 2011.
30. Fjeldsoe BS, Marshall AL, Miller YD: Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med 2009, 36:165-173. 10.1016/j.amepre.2008.09.040
31. Aggleton P: Behavior change communication strategies. AIDS Educ Prev 1997, 9:111-123.
32. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA: Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 2010, 376:1838-1845. 10.1016/S0140-6736(10)61997-6
33. Bender B, Milgrom H, Apter A: Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol 2003, 112:489-494. 10.1016/S0091-6749(03)01718-4
34. Pinnock H, Bawden R, Proctor S, Wolfe S, Scullion J, Price D, Sheikh A: Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ 2003, 326:477-479. 10.1136/bmj.326.7387.477
35. Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D, Sheikh A, Tarassenko L, Pagliari C, Pinnock H: Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ 2012, 344:e1756. 10.1136/bmj.e1756
36. Pocket Guide for Asthma Management and PreventionDocuments/ResourcesGINA Available from: http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2014_Jun11.pdf
37. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RFT, Juniper EF, Ayres JG, Kemp L, Blyth A, Wilson ECF, Wolfe S, Freeman D, Mugford HM, Murdoch J, Harvey I: Leukotriene antagonists as first-line or add-on asthma-controller therapy. New Engl J Med 2011, 364:1695-1707. 10.1056/NEJMoa1010846
38. Marra CA, Cibere J, Grubisic M, Grindrod KA, Gastonguay L, Thomas JM, Embley P, Colley L, Tsuyuki RT, Khan KM, Esdaile JM: Pharmacist-initiated intervention trial in osteoarthritis: a multidisciplinary intervention for knee osteoarthritis. Arthritis Care Res 2012, 64:1837-1845. 10.1002/acr.21763
39. Marra CA, Cibere J, Tsuyuki RT, Soon JA, Esdaile JM, Gastonguay L, Oteng B, Embley P, Colley L, Enenajor G, Kok R: Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis Rheum 2007, 57:1238-1244. 10.1002/art.23019
40. Tsao NW, Marra CA, Lynd LD, Thomas JM, Ferreira E: Community pharmacist surveillance of hypertension in pregnancy: are we ready for prime time? Can Pharm J 2014, 147:307-315. 10.1177/1715163514543898
41. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB: Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004, 113:59-65. 10.1016/j.jaci.2003.09.008
42. Schatz M, Zeiger RS, Yang SJ, Weinstein AG, Chen W, Saris-Baglama RN, Turner-Bowker DM: Development and preliminary validation of the adult asthma adherence questionnaire. J Allergy Clin Immunol Pract 2013, 1:280-288. 10.1016/j.jaip.2013.03.001
43. Hahn SR, Park J, Skinner EP, Yu-Isenberg KS, Weaver MB, Crawford B, Flowers PW: Development of the ASK-20 adherence barrier survey. Curr Med Res Opin 2008, 24:2127-2138. 10.1185/03007990802174769
44. McHorney CA, Victor Spain C, Alexander CM, Simmons J: Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims. Clin Ther 2009, 31:2584-2607. 10.1016/j.clinthera.2009.11.030
45. British Columbia Ministry of Health: PharmaNet. What is PharmaNet? 2014. http://www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html
46. Population Data BC: Population Data BC. 2014. https://www.popdata.bc.ca/
47. Hess LM, Raebel MA, Conner DA, Malone DC: Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40:1280-1288. 10.1345/aph.1H018
48. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK: Evaluation of impairment of health related quality-of-life in asthma - development of a questionnaire for use in clinical-trials. Thorax 1992, 47:76-83. 10.1136/thx.47.2.76
49. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM: Sample size calculator for cluster randomized trials. Comput Biol Med 2004, 34:113-125. 10.1016/S0010-4825(03)00039-8
50. Donner A, Klar N: Design and Analysis of Cluster Randomization Trials in Health Research. London: Arnold; 2000.
51. Evans CD, Eurich DT, Lamb DA, Taylor JG, Jorgenson DJ, Semchuk WM, Mansell KD, Blackburn DF: Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manage Care Pharm 2009, 15:476-484.
52. Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH, Hypertension RG: Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial. BMJ 2007, 335:1030. 10.1136/bmj.39360.617986.AE
53. Smeeth L, Ng ES: Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC trial of the assessment and management of older people in the community. Control Clin Trials 2002, 23:409-421. 10.1016/S0197-2456(02)00208-8
54. Cosby RH, Howard M, Kaczorowski J, Willan AR, Sellors JW: Randomizing patients by family practice: sample size estimation, intracluster correlation and data analysis. Fam Pract 2003, 20:77-82. 10.1093/fampra/20.1.77
55. Heisler M, Hofer TP, Klamerus ML, Schmittdiel J, Selby J, Hogan MM, Bosworth HB, Tremblay A, Kerr EA: Study protocol: the Adherence and Intensification of Medications (AIM) study-a cluster randomized controlled effectiveness study. Trials 2010, 11:95. 10.1186/1745-6215-11-95
56. Pladevall M, Brotons C, Gabriel R, Arnau A, Suarez C, de la Figuera M, Marquez E, Coca A, Sobrino J, Divine G, Heisler M, Williams LK, COM99 Study Group: Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (The COM99 Study). Circulation 2010, 122:1183-U81. 10.1161/CIRCULATIONAHA.109.892778
57. Omran D, Guirguis LM, Simpson SH: Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes. Can J Diab 2012, 36:292-299. 10.1016/j.jcjd.2012.07.002
58. Zafari Z, Sadatsafavi M, FitzGerald M, Lynd L, Marra C: The humanistic and economic impact of following evidence-based asthma controller therapy: a simulation study. Value Health 2013, 16:A235.
59. Newell DJ: Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 1992, 21:837-841. 10.1093/ije/21.5.837
60. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637-639. 10.1001/jama.1996.03540080059030
61. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL: Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007, 120:1146-1152. 10.1016/j.jaci.2007.07.055
62. Zafari Z, Lynd LD, FitzGerald JM, Sadatsafavi M: Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: a simulation study. J Allergy Clin Immunol 2014, 134:908-915. 10.1016/j.jaci.2014.04.009
63. Urquhart J: The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997, 32:345-356. 10.2165/00003088-199732050-00001
64. Catwell L, Sheikh A: Evaluating eHealth interventions: the need for continuous systemic evaluation. PLoS Med 2009, 6:e1000126. 10.1371/journal.pmed.1000126